Total Payments
$25,274
2024 Payments
$2,596
Companies
66
Transactions
340
Medicare Patients
11,470
Medicare Billing
$6.1M
Payment Breakdown by Category
Consulting$14,369 (56.9%)
Food & Beverage$7,002 (27.7%)
Travel$1,907 (7.5%)
Other$1,500 (5.9%)
Education$496.42 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,369 | 7 | 56.9% |
| Food and Beverage | $7,002 | 313 | 27.7% |
| Travel and Lodging | $1,907 | 8 | 7.5% |
| Honoraria | $1,500 | 1 | 5.9% |
| Education | $496.42 | 11 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $6,562 | 48 | $0 (2024) |
| Lilly USA, LLC | $5,341 | 44 | $0 (2024) |
| Gilead Sciences, Inc. | $4,718 | 9 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,741 | 8 | $0 (2024) |
| G1 Therapeutics, Inc. | $1,500 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $694.45 | 34 | $0 (2024) |
| Daiichi Sankyo Inc. | $534.45 | 9 | $0 (2024) |
| PFIZER INC. | $340.48 | 18 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $288.69 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $246.00 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,596 | 119 | AstraZeneca Pharmaceuticals LP ($408.39) |
| 2023 | $1,639 | 70 | AstraZeneca Pharmaceuticals LP ($397.76) |
| 2022 | $658.40 | 27 | AstraZeneca Pharmaceuticals LP ($132.69) |
| 2021 | $4,998 | 7 | AstraZeneca Pharmaceuticals LP ($1,859) |
| 2020 | $1,332 | 3 | AstraZeneca Pharmaceuticals LP ($910.00) |
| 2019 | $8,000 | 53 | Lilly USA, LLC ($5,159) |
| 2018 | $619.60 | 19 | AstraZeneca Pharmaceuticals LP ($256.12) |
| 2017 | $5,429 | 42 | Gilead Sciences Inc ($4,659) |
All Payment Transactions
340 individual payment records from CMS Open Payments — Page 14 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/27/2017 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Oncology | ||||||
| 06/15/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Anemia | ||||||
| 06/08/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/06/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $11.56 | General |
| Category: Oncology | ||||||
| 05/24/2017 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $115.38 | General |
| Category: Hematology / Oncology | ||||||
| 05/22/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $7.13 | General |
| Category: Hematology/Oncology | ||||||
| 05/02/2017 | Kyowa Kirin, Inc. | SANCUSO (Drug), FARESTON, IXEMPRA | Food and Beverage | In-kind items and services | $12.01 | General |
| Category: ANTIEMETIC - 5HT3 INHIBITOR | ||||||
| 04/28/2017 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Oncology | ||||||
| 04/26/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: Anemia | ||||||
| 04/06/2017 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $14.29 | General |
| Category: Oncology | ||||||
| 03/23/2017 | Bayer HealthCare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: Oncology | ||||||
| 03/21/2017 | Lexicon Pharmaceuticals, Inc. | Xermelo (Drug) | Food and Beverage | In-kind items and services | $10.51 | General |
| Category: Carcinoid Syndrome Diarrhea | ||||||
| 03/14/2017 | Lilly USA, LLC | ALIMTA (Drug), ERBITUX, CYRAMZA | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: Oncology | ||||||
| 02/23/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Oncology | ||||||
| 01/24/2017 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 2,511 | 105,807 | $4.1M | $1.3M |
| 2022 | 58 | 2,961 | 100,277 | $4.2M | $1.6M |
| 2021 | 54 | 2,837 | 78,329 | $4.0M | $1.6M |
| 2020 | 60 | 3,161 | 96,283 | $4.1M | $1.6M |
Total Patients
11,470
Total Services
380,696
Medicare Billing
$6.1M
Procedure Codes
225
All Medicare Procedures & Services
225 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 8,800 | $800,800 | $382,495 | 47.8% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 13 | 8,260 | $421,260 | $195,419 | 46.4% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 5,040 | $443,520 | $192,141 | 43.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 36 | 6,060 | $151,500 | $111,689 | 73.7% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 14 | 1,900 | $180,500 | $68,109 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 243 | 624 | $124,800 | $58,230 | 46.7% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 12 | 6,800 | $136,000 | $55,034 | 40.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 160 | 422 | $166,690 | $42,362 | 25.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 402 | 631 | $94,650 | $40,205 | 42.5% |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 2023 | 19 | 408 | $285,600 | $39,726 | 13.9% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 48 | 5,080 | $121,920 | $28,133 | 23.1% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 29 | 85 | $29,750 | $15,004 | 50.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 50 | 32,640 | $65,280 | $12,874 | 19.7% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 15 | 3,185 | $286,650 | $12,763 | 4.5% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 18 | 27 | $22,275 | $9,447 | 42.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 26 | 140 | $22,400 | $7,866 | 35.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 85 | 159 | $23,850 | $7,486 | 31.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 71 | 123 | $16,605 | $7,469 | 45.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 53 | 121 | $21,780 | $5,949 | 27.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 114 | 499 | $24,950 | $5,889 | 23.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $13,420 | $4,540 | 33.8% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 28 | 1,340 | $16,080 | $4,230 | 26.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 145 | 347 | $19,085 | $3,662 | 19.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 49 | 155 | $14,725 | $3,377 | 22.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 36 | $7,200 | $3,330 | 46.3% |
About Dr. Elke Friedman, MD
Dr. Elke Friedman, MD is a Hematology & Oncology healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1629073473.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Elke Friedman, MD has received a total of $25,274 in payments from pharmaceutical and medical device companies, with $2,596 received in 2024. These payments were reported across 340 transactions from 66 companies. The most common payment nature is "Consulting Fee" ($14,369).
As a Medicare-enrolled provider, Friedman has provided services to 11,470 Medicare beneficiaries, totaling 380,696 services with total Medicare billing of $6.1M. Data is available for 4 years (2020–2023), covering 225 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Richmond, VA
- Active Since 06/17/2005
- Last Updated 03/17/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1629073473
Products in Payments
- Zydelig (Drug) $4,644
- IMFINZI (Drug) $3,210
- IMFINZI (Biological) $1,921
- Stivarga (Drug) $1,671
- COSELA (Drug) $1,500
- CYRAMZA (Drug) $880.26
- LYNPARZA (Drug) $563.39
- Enhertu (Drug) $434.93
- FASLODEX (Drug) $257.19
- KISQALI (Drug) $245.73
- KEYTRUDA (Biological) $191.61
- Lenvima (Drug) $169.82
- OPDIVO (Biological) $161.39
- Onivyde (Drug) $159.31
- NINLARO (Drug) $158.24
- VERZENIO (Drug) $139.23
- MEKINIST (Drug) $136.16
- ENHERTU (Biological) $135.30
- TAGRISSO (Drug) $131.69
- Revlimid (Drug) $129.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Richmond
Dr. Victor Yazbeck, M.d, M.D
Hematology & Oncology — Payments: $390,374
Hematology & Oncology $390,374
Attique Samdani, M.d, M.D
Hematology & Oncology — Payments: $146,382
Hematology & Oncology $146,382
Dr. Asit Paul, M.d., Ph.d.,, M.D., PH.D.,
Hematology & Oncology — Payments: $7,490
Hematology & Oncology $7,490
Dr. Ghulam Qureshi, M.d, M.D
Hematology & Oncology — Payments: $7,032
Hematology & Oncology $7,032
Gisa-Beate Schunn, M.d, M.D
Hematology & Oncology — Payments: $5,929
Hematology & Oncology $5,929
Erin Alesi, Md, MD
Hematology & Oncology — Payments: $5,636
Hematology & Oncology $5,636